

30 Day Change Notice Effective Date: July 1, 2023

NEW NON-PREFERRED DRUGS		
THERAPEUTIC CLASS	PA REQUIRED NON-PREFERRED	
Blood Formation, Coagulation, and Thrombosis	Rolvedon	
Agents: Colony Stimulating Factors	Stimufend	
Central Nervous System (CNS) Agents: Attention	Xelstrym	
Deficit Hyperactivity Disorder Agents		
Central Nervous System (CNS) Agents: Multiple	Tascenso ODT	
Sclerosis*		
Endocrine Agents: Diabetes – Insulin	Basaglar Tempo Pen	
	Humalog U-100 Tempo Pen	
	Lyumjev Tempo Pen	
Topical Agents: Immunomodulators	Hyftor	

NEW CLINICAL PA REQUIRED PREFERRED DRUGS		
THERAPEUTIC CLASS		
Blood Formation, Coagulation, and Thrombosis	Kovaltry	
Agents: Hemophilia Factor*		

THERAPEUTIC CATEGORIES WITH CHANGES IN CRITERIA		
Central Nervous System (CNS) Agents: Attention Deficit Hyperactivity Disorder Agents		
Endocrine Agents: Diabetes – Insulin		
Central Nervous System (CNS) Agents: Antidepressants*		
Central Nervous System (CNS) Agents: Atypical Antipsychotics*		
Central Nervous System (CNS) Agents: Anticonvulsants*		
Central Nervous System (CNS) Agents: Anti-Migraine Agents, Cluster Headache		

REVISED THERAPEUTIC CATEGORY CRITERIA		
THERAPEUTIC CLASS	SUMMARY OF CHANGE	
Central Nervous	Add AR to Xelstrym (a PA is required for patients younger than 6 years)	
System (CNS)		
Agents: Attention		
Deficit		
Hyperactivity		
Disorder Agents		
Endocrine Agents:	ADDITIONAL TEMPO PEN CRITERIA	
Diabetes – Insulin	 Must have had an inadequate clinical response or documentation 	
	of medical necessity beyond convenience for why the patient	
	cannot use the corresponding FlexPens or Kwikpens	

Date of Notice: 6/1/2023



30 Day Change Notice Effective Date: July 1, 2023

Central Nervous System (CNS) Agents: Antidepressants*	 ADDITIONAL DEXTROMETHORPHAN/BUPROPION (AUVELITY) CRITERIA Must provide documentation for patient's inability to use the individual drugs Must have an inadequate clinical response of at least 30 days with ALL of the following:
	 ONE dopamine/norepinephrine reuptake inhibitor (DNRI) ONE selective norepinephrine reuptake inhibitor (SNRI) ONE tricyclic antidepressant (TCA) TWO selective serotonin reuptake inhibitors (SSRIs) (ONE of which must be either vilazodone (Viibryd) OR vortioxetine (Trintellix))
	PSYCHIATRIST EXEMPTION: Prescribers (as identified below) are exempt from prior authorization of any non-preferred antidepressant, or step therapy of any preferred branddrug, in the standard tablet/capsule dosage forms. Other dosage forms may still require prior authorization. The exemption will be processed by the claims system when the pharmacy has submitted the prescriber on the claim using the individual national provider identifier (NPI) for the prescriber.
	Prescribers are defined as: FFS: Physicians who are registered with Ohio Medicaid as having a specialty in psychiatry MCOs: Physicians with a specialty in psychiatry, nurse practitioners certified in psychiatric mental health, or clinical nurse specialists certified in psychiatric mental health, who are credentialed via with the Ohio Department of Medicaid managed care plan.
Central Nervous System (CNS) Agents: Atypical Antipsychotics*	PSYCHIATRIST EXEMPTION: Prescribers (as identified below) are exempt from prior authorization of any non-preferred second-generation antipsychotic, or step therapy of any preferred branddrug, in the standard tablet/capsule and long-acting injectable dosage forms Other dosage forms may still require prior authorization. The exemption will be processed by the claims system when the pharmacy has submitted the prescriber on the claim using the individual national provider identifier (NPI) for the prescriber
	Prescribers are defined as: FFS: Physicians who are registered with Ohio Medicaid as having a specialty in psychiatry MCOs: Physicians with a specialty in psychiatry, nurse practitioners certified in psychiatric mental health, or clinical nurse specialists certified in psychiatric mental health, who are credentialed via with the Ohio Department of Medicaid managed care plan.
Central Nervous System (CNS)	NEUROLOGIST EXEMPTION: Prescriptions submitted from a prescriber who is registered credentialed as a

Date of Notice: 6/1/2023



30 Day Change Notice Effective Date: July 1, 2023

	Elloctive Buto: Guly 1, 2020
Agents:	neurology specialty with Ohio Medicaid AND for drugs that are used only for
Anticonvulsants*	seizures, there must have been an inadequate clinical response of at least 30
	days with one preferred drug. This provision applies only to the standard
	tablet/capsule dosage form and does not apply to brand products with available
	generic alternatives.
Central Nervous System (CNS) Agents: Anti- Migraine Agents, Cluster Headache	QL – Emgality: 3 doses per 30 days (for initial loading dose only), then 1 dose per 30 days thereafter

Date of Notice: 6/1/2023